Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study

We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, after a maximum follow-up of five years. Patients were included according to the French marketing authorization in 2016 (i.e. pat...

Full description

Bibliographic Details

Published in:	Annals of hematology Vol. 35; no. 1; pp. 130 - 137
Main Authors:	Dartigeas, Caroline, Quinquenel, Anne, Ysebaert, Loïc, Dilhuydy, Marie-Sarah, Anglaret, Bruno, Slama, Borhane, Le Du, Katell, Tardy, Stéphanie, Tchernonog, Emmanuelle, Orfeuvre, Hubert, Voillat, Laurent, Guidez, Stéphanie, Malfuson, Jean-Valère, Dupuis, Sandrine, Deslandes, Marine, Feugier, Pierre, Leblond, Véronique
Format:	Journal Article
Language:	English
Published:	Germany Springer Verlag 06-03-2024
Subjects:	Life Sciences Chronic lymphocytic leukemia Effectiveness Safety Ibrutinib Real-world evidence
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!